Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma
NCT06941688 · Seoul National University Hospital · PHASE2 · terminated · last registry update 2025-04-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “slow recruitment” | – | Registry record, Seoul National University Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RRM1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-22Phase 3 first posted: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, Investigator's choice of Chemotherapy + Azenosertib (NCT07546500)
- 2026-03-18Phase 3 first posted: Kite, A Gilead Company, KITE-753 + Axicabtagene Ciloleucel (NCT07479797)
- 2026-03-09Phase 3 first posted: First Affiliated Hospital of Guangxi Medical University, Becotatug Vedotin + Sintilimab (NCT07459296)
- 2026-03-06Results posted on the registry: Hoffmann-La Roche, Mosunetuzumab + Polatuzumab vedotin (NCT05171647)
- 2026-02-13Phase 3 first posted: Hutchmed, HMPL-760 + HMPL-760 Placebo (NCT07409428)
- 2025-12-16Phase 3 first posted: GlaxoSmithKline, Mocertatug rezetecan + Paclitaxel (NCT07286266)
- 2025-10-31Phase 3 first posted: Memorial Sloan Kettering Cancer Center, Fludarabine + Cyclophosphamide (NCT07223021)
- 2025-10-09Phase 3 first posted: Eli Lilly and Company, Sofetabart Mipitecan + Paclitaxel (NCT07213804)
- 2025-10-09Phase 3 first posted: Incyte Corporation, INCB123667 + Investigator's choice of chemotherapy (NCT07214779)
- 2025-09-18Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Ipilimumab (NCT03036098)
- 2025-09-15Phase 3 first posted: BioNTech SE, Pumitamig + Nab-paclitaxel/Paclitaxel (NCT07173751)
- 2025-07-31Phase 3 first posted: NRG Oncology, Cisplatin + Fluorouracil (NCT07097142)
- 2025-07-03Results posted on the registry: AstraZeneca, Durvalumab + Cisplatin (NCT03732677)
- 2025-05-20Results posted on the registry: Janssen Research & Development, LLC, Cilta-cel + Pomalidomide (NCT04181827)
- 2025-04-20Phase 3 first posted: Hansoh BioMedical R&D Company, HS-20093 + Gemcitabine combined with docetaxel (NCT06935409)
- 2025-04-09Phase 3 first posted: Janssen Research & Development, LLC, TAR-210 + Mitomycin C (NCT06919965)
- 2025-02-24Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06841354)
- 2024-12-19Phase 3 first posted: Immatics US, Inc., IMA203 + nivolumab plus relatlimab (NCT06743126)
- 2024-12-03Phase 3 first posted: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, High intensity therapies + Low intensity therapies (NCT06713837)
- 2024-10-16Results posted on the registry: National Cancer Institute (NCI), Cisplatin + Triapine (NCT02595879)
- 2024-10-02Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Cisplatin (NCT06623422)
- 2024-10-01Phase 3 first posted: InnoPharmax Inc., D07001-Softgel Capsules + Placebo (NCT06622057)
- 2024-10-01Phase 3 first posted: Genmab, Rina-S + Paclitaxel (NCT06619236)
- 2024-09-26Phase 3 first posted: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, BMS-986393 + Cyclophosphamide (NCT06615479)
- 2024-09-23Phase 3 first posted: Arcus Biosciences, Inc., Quemliclustat + Placebo (NCT06608927)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision